Sonnet biotherapeutics to present preclinical data on son-080 for chemotherapy-induced peripheral neuropathy (cipn) at the aacr 2024 annual meeting

Princeton, nj / accesswire / march 19, 2024 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of son-080 (recombinant human interleukin-6 or rhil-6) in cipn will be presented in a poster session at the upcoming american association for cancer research (aacr) annual meeting 2023, to be held april 5-10, in san diego, california. presentation details: title: low dose interleukin-6 (son-080) for neuropathies: toxicology and clinical plans session title: pharmacology and pharmacogenetics presentation type: poster session date and time: wednesday april 10, 2024, 9:00 am - 12:30 pm abstract number: 7181 location: poster section 24 poster board number: 22 about sonnet biotherapeutics holdings, inc. sonnet biotherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action.
SONN Ratings Summary
SONN Quant Ranking